Long-term benefits of TUDCA supplement in ARSACS zebrafish model
- PMID: 40659819
- PMCID: PMC12260040
- DOI: 10.1038/s41598-025-10850-0
Long-term benefits of TUDCA supplement in ARSACS zebrafish model
Abstract
Autosomal recessive spastic ataxia of Charlevoix-Saguenay (ARSACS) is an early-onset neurodevelopmental and neurodegenerative disorder characterized by ataxia, spasticity, and peripheral neuropathy. However, several studies have highlighted that some patients also experience cognitive, emotional and social deficits, suggesting a more complex clinical picture that extends beyond motor symptoms. Building on these findings, this study aimed to: (i) investigate locomotor, social and cognitive deficits in adult sacs-/- zebrafish versus wild-type (WT) controls through behavioural tests; (ii) identify molecular patterns associated with the adult disease phenotype using transcriptomic and proteomic analyses of sacs-/- and WT brains; (iii) evaluate the effectiveness of long-term treatment with tauroursodeoxycholic acid (TUDCA) on behavioural outcomes and omics profiles in the zebrafish sacs-/- model. Our findings indicate impairments in cognitive, social, and emotional behaviors in aged sacs-/- zebrafish, which resemble some deficits observed in human patients. Transcriptomic and proteomic analyses of adult brains identified alterations in genes related to circadian rhythms and neuroinflammation. Notably, disruptions in sleep and circadian rhythms are frequently reported in individuals with cerebellar ataxia and may contribute to cognitive and behavioral changes. Long-term treatment with TUDCA, a neuroprotective molecule, was associated with partial improvements in social and cognitive behaviors and modifications in omics profiles in the zebrafish model. These results support the potential of further exploring TUDCA in future preclinical and clinical studies, while also emphasizing the need for additional investigations to better understand its mechanisms of action.
Keywords: ARSACS; Ataxia; Neurodegeneration; TUDCA; Zebrafish.
© 2025. The Author(s).
Conflict of interest statement
Declarations. Competing interests: The authors declare no competing interests. Ethics approval: This study does not include human samples. All animal procedures were authorized by the University of Pisa Animal Ethics Committee and the Italian Ministry of Health (n° 620/2024-PR). The study is reported in accordance with ARRIVE guidelines.
Figures








Similar articles
-
Short-Term Memory Impairment.2024 Jun 8. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan–. 2024 Jun 8. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan–. PMID: 31424720 Free Books & Documents.
-
The Black Book of Psychotropic Dosing and Monitoring.Psychopharmacol Bull. 2024 Jul 8;54(3):8-59. Psychopharmacol Bull. 2024. PMID: 38993656 Free PMC article. Review.
-
S100B Mitigates Cytoskeletal and Mitochondrial Alterations in a Glial Cell Model of Autosomal Recessive Spastic Ataxia of Charlevoix-Saguenay.Mol Neurobiol. 2025 Sep;62(9):12296-12306. doi: 10.1007/s12035-025-05057-3. Epub 2025 May 19. Mol Neurobiol. 2025. PMID: 40389788 Free PMC article.
-
Intrathecal baclofen for treating spasticity in children with cerebral palsy.Cochrane Database Syst Rev. 2015 Nov 13;2015(11):CD004552. doi: 10.1002/14651858.CD004552.pub2. Cochrane Database Syst Rev. 2015. PMID: 26563961 Free PMC article.
-
Idiopathic (Genetic) Generalized Epilepsy.2024 Feb 12. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan–. 2024 Feb 12. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan–. PMID: 31536218 Free Books & Documents.
References
-
- Bouhlal, Y., Amouri, R., Euch-Fayeche, E., Hentati, F. & G. & Autosomal recessive spastic ataxia of Charlevoix–Saguenay: An overview. Parkinsonism Relat. Disord. 17, 418–422 (2011). - PubMed
-
- Engert, J. C. et al. ARSACS, a spastic ataxia common in Northeastern québec, is caused by mutations in a new gene encoding an 11.5-kb ORF. Nat. Genet.24, 120–125 (2000). - PubMed
-
- Anderson, J. F., Siller, E. & Barral, J. M. The neurodegenerative-disease-related protein sacsin is a molecular chaperone. J. Mol. Biol.411, 870–880 (2011). - PubMed
-
- Anderson, J. F., Siller, E. & Barral, J. M. The Sacsin repeating region (SRR): A novel Hsp90-Related Supra-Domain associated with neurodegeneration. J. Mol. Biol.400, 665–674 (2010). - PubMed
-
- Ali, Z. et al. Novel SACS mutations associated with intellectual disability, epilepsy and widespread supratentorial abnormalities. J. Neurol. Sci.371, 105–111 (2016). - PubMed
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources